Declaration of interest
S. Gauthier discloses clinical trial support from Lilly, Roche, TauRx and Lundbeck; he is a DSMB member for ADCS, ATRI, API and Eisai; he is a scientific advisor for AbbVie, Advantage, Alzheon, Axovant, Boehringer-Ingelheim, Firalis, Heptares, IntelGen, Kalgene, Lilly, Lundbeck, Novartis, Otsuka, Servier, Sanofi, Schwabe, Takeda, TauRx, TVM Capital and Roche. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.